Response to COVID-19 Vaccines in Patients Receiving Intensified Post-ASCT Therapy with Daratumumab, Lenalidomide, Bortezomib (Dara-VR) Due to Ultra-High Risk (UHiR) Newly Diagnosed Myeloma (NDMM) or Primary Plasma Cell Leukemia (pPCL): Exploratory Analysis of the UK Optimum/Muknine Trial
Matthew Jenner(University Hospital Southampton NHS Foundation Trust), Martin Kaiser(Royal Marsden NHS Foundation Trust), Kristian M. Bowles(University of East Anglia), Mamta Garg(Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo), Gordon Cook(University of Leeds), Christina Messiou(Institute of Cancer Research), Mark T. Drayson(Institute of Immunology), Guy Pratt(University Hospitals Birmingham NHS Foundation Trust), Anand Lokare(University Hospitals Coventry and Warwickshire NHS Trust), Roger G. Owen(Leeds Teaching Hospitals NHS Trust), Sarah Brown(University of Leeds), Emma Ingleson(University of Leeds), Sadie Roberts(University of Leeds), Andrew Hall(University of Leeds), Graham Jackson(Newcastle College), Ruth M. de Tute(St James's University Hospital), Alexandra Pitchford(University of Leeds), Sian Faustini(University of Birmingham)
Cited by 2
Related Papers
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
|New England Journal of Medicine|2003|1.8k
Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients
|Blood|2020|657
Comparative effectiveness of MRI in breast cancer (COMICE) trial: a randomised controlled trial
|The Lancet|2010|640
Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2008|605